Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT06196788

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Led by Fudan University · Updated on 2024-03-21

30

Participants Needed

1

Research Sites

200 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic Cancer.

CONDITIONS

Official Title

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand and willing to sign informed consent
  • Age between 18 and 80 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Histologically or cytologically confirmed advanced pancreatic adenocarcinoma
  • Primary pancreatic cancer without prior major anti-cancer treatments
  • Locally advanced or metastatic pancreatic cancer
  • At least one measurable lesion according to RECIST criteria
  • Expected survival of at least 3 months
  • Adequate organ function based on laboratory blood tests
  • Willingness and ability to comply with study procedures
Not Eligible

You will not qualify if you...

  • Pregnant or nursing women
  • Previous treatment with anti-tumor chemotherapy, radiotherapy, or other treatments
  • Diagnosis of pancreatic cancer other than adenocarcinoma
  • Inflammation of the digestive tract (e.g., pancreatitis, cholecystitis, cholangitis)
  • Severe uncontrollable diseases affecting study compliance or result interpretation
  • History of cardiovascular or cerebrovascular accidents
  • Allergy to study drugs
  • Other serious illnesses that may affect treatment safety as judged by the researcher

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

Loading map...

Research Team

Y

Ying Yang, MD

CONTACT

G

Guopei Luo, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here